Immunome IMNM
NASDAQ IMNM
$17.92 +1.15 (+6.86%)
At close: Oct 20, 2026 · 4:00 PM EDT

Immunome (IMNM) Current Leases (2019)

Updated

Immunome's Current Leases came in at $239,000 for Q4 2019.

Analysis

Immunome (IMNM) Current Leases (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn -
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn -
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn -
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn -
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn -
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn -
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn -
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn -
10 Immunome 2.04 Bn 6.69 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 239,000.00
API Access

Immunome Current Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-leases&ticker=IMNM&period=max&api_key=YOUR_API_KEY